![]() |
|||
|
|||
This Issue in the Journal
Seasonal variation in vitamin D levels in the
Canterbury, New Zealand population in relation to available UV
radiation
John Livesey, Peter Elder, M Jane Ellis, Richard McKenzie, Ben Liley, Chris Florkowski We measured blood vitamin D levels in volunteers and
patients in Canterbury (119 females, 82 males; median age 45 years, range
18 to 83) and found that most people are vitamin D deficient most of the
time when compared to the latest international recommendations, particularly in
late winter and early spring. We then used mathematical modelling to predict the
daily amount of vitamin D supplementation required to correct this deficiency
and found that about 2600 international units per day is needed. This is well
above current New Zealand guidelines of 1600 international units per day and
suggests that the widespread consumption of relatively high prescription
strength doses of vitamin D is likely to be needed to ensure the optimal health
of the Canterbury population by reducing the incidence of chronic diseases such
as fractures in older people, cancer, and muscle weakness.
Vitamin D and muscle strength in patients with
previous fractures
Charles A Inderjeeth, Denise Glennon, Anthony Petta, Jessamine Soderstrom, Irene Boyatzis, Jeffrey Tapper Vitamin D deficiency is a common and important problem in
older people and it is an important factor in osteoporosis. Vitamin D deficiency
may also be an important cause of poor muscle strength and falls, especially in
the elderly. Our study at a hospital in Western Australia studied vitamin D
levels and leg muscle strength in 99 women aged over 60 and found that low
vitamin D levels were associated with poor leg muscle strength. Correcting
Vitamin D deficiency may be important in reducing fracture through both reducing
osteoporosis and reducing falls through improved muscle strength.
The failure to diagnose inborn errors of metabolism
in New Zealand: the case for expanded newborn screening
Callum Wilson, Nicola J Kerruish, Bridget Wilcken, Esko Wiltshire, Dianne Webster Inborn errors of metabolism refer to a group of rare genetic
chemical disorders. Children with these conditions often present with serious
symptoms such as coma. However because these symptoms are usually due to other
more common conditions clinicians may not investigate the patient for an
underlying metabolic disorder. This is unfortunate as treatment (if commenced
very early) dramatically improves the outcome. This paper reports the findings
of a nationwide 3-year surveillance study that shows that these disorders have
been under diagnosed in recent years in New Zealand. A small number of children
are likely to have died yearly as a result.
The recent introduction of expanded newborn screening,
a process whereby key chemicals are measured in the neonatal Guthrie card blood
test prior to the child becoming sick, will hopefully improve this situation.
The paper further discusses this new form of screening, its advantages and
limitations.
Phenylketonuria—the lived
experience
Nicole Frank, Ruth Fitzgerald, Michael Legge This research is based on interviews with eight people who
live with phenylketonuria (PKU) in New Zealand. PKU is a severe genetic disorder
affecting the body’s ability to produce certain proteins which help to
break down food into its constituent components. It is treated by following a
very strict diet which must begin at birth and be followed for life. People who
live with the disease describe the effect of it as turning them into expert
negotiators in the medical, social, and personal spheres of their lives. They
recount the consistent juggling of the risk of their unknown futures with the
conflicting demands for expressing affection and pleasure through shared eating
with family and friends versus the need to adhere very strictly to their diets
to try to retain their health and mental facilities.
Glycaemic control and antibody status among Waikato,
New Zealand patients with newly diagnosed Type 1
diabetes
Doron Hickey, Grace Joshy, Peter Dunn, David Simmons, Ross Lawrenson Type 1 diabetes is categorised as either being positive or
negative for various auto-antibodies related to pancreatic function. It has not
been established whether the actual titres of anti-GAD or anti-IA2 antibodies at
diagnosis have prognostic implications, although the presence of anti-GAD is
believed to be indicative of beta-cell destruction. Our study did not show any
statistically significant associations between antibody status and subsequent
hospital admission for diabetic ketoacidosis. But a positive anti-IA2 status was
associated with better glycaemic control (HbA1c<10%). If there is evidence of
antibodies to IA2 present then this is a predictor of better glycaemic control
and it may be that these patients will have less complications than those who
are anti-IA2 negative. We believe this is the first time this finding has been
reported.
|
|||
| Current
issue | Search journal |
Archived issues | Classifieds
| Hotline (free ads) Subscribe | Contribute | Advertise | Contact Us | Copyright | Other Journals |